Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 References  














Dihydrexidine






Español
Српски / srpski
Srpskohrvatski / српскохрватски
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Dihydrexidine
Clinical data
ATC code
  • none
Identifiers
  • 5,6,6a,7,8,12b-hexahydro-benzo(a)phenanthridine-10,11-diol

CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H17NO2
Molar mass267.328 g·mol−1
3D model (JSmol)
  • c1ccc2c(c1)CN[C@H]3[C@H]2c4cc(c(cc4CC3)O)O

  • InChI=1S/C17H17NO2/c19-15-7-10-5-6-14-17(13(10)8-16(15)20)12-4-2-1-3-11(12)9-18-14/h1-4,7-8,14,17-20H,5-6,9H2/t14-,17-/m1/s1 ☒N

  • Key:BGOQGUHWXBGXJW-RHSMWYFYSA-N ☒N

 ☒NcheckY (what is this?)  (verify)

Dihydrexidine (DAR-0100) is a moderately selective full agonist at the dopamine D1 and D5 receptors.[1] It has approximately 10-fold selectivity for D1 and D5 over the D2 receptor.[2] Although dihydrexidine has some affinity for the D2 receptor, it has functionally selective (highly biased) D2 signaling,[3] thereby explaining why it lacks D2 agonist behavioral qualities.[4]

Dihydrexidine has shown impressive antiparkinson effects in the MPTP-primate model,[5] and has been investigated for the treatmentofParkinson's disease.[6] In an early clinical trial the drug was given intravenously and led to profound hypotensionsodevelopment was halted.[7] The drug was resurrected when it was shown that smaller subcutaneous doses were safe.[8] This led to a pilot study in schizophrenia[9] and current clinical trials to assess its efficacy in improving the cognitive and working memory deficitsinschizophrenia and schizotypal disorder.

There have been several reviews of relevance to the compound.[10][11][12]

References[edit]

  1. ^ Lovenberg TW, Brewster WK, Mottola DM, Lee RC, Riggs RM, Nichols DE, Lewis MH, Mailman RB (1989). "Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist". Eur J Pharmacol. 166 (1): 111–113. doi:10.1016/0014-2999(89)90690-0. PMID 2572425.
  • ^ Mottola DM, Brewster WK, Cook LL, Nichols DE, Mailman RB (1992). "Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist". J Pharmacol Exp Ther. 262 (1): 383–393. PMID 1352553.
  • ^ Kilts, JD.; et al. (2002). "Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs". J Pharmacol Exp Ther. 301 (3): 1179–89. doi:10.1124/jpet.301.3.1179. PMID 12023553.
  • ^ Darney KJ Jr, Lewis MH, Brewster WK, Nichols DE, Mailman RB (1991). "Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist". Neuropsychopharmacology. 5 (3): 187–195. PMID 1684499.
  • ^ Taylor JR, Lawrence MS, Redmond DE Jr, Elsworth JD, Roth RH, Nichols DE, Mailman RB (1991). "Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys". Eur J Pharmacol. 199 (3): 389–391. doi:10.1016/0014-2999(91)90508-N. PMID 1680717.
  • ^ Mailman RB, Nichols DE (1998). "Dopamine D1 receptor agonists as antiparkinson drugs". Trends Pharmacol. Sci. 19 (7): 255–256. doi:10.1016/S0165-6147(98)01219-X. PMID 9703756.
  • ^ Blanchet PJ, Fang J, Gillespie M, Sabounjian L, Locke KW, Gammans R, Mouradian MM, Chase TN (1998). "Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease". Clin. Neuropharmacol. 21 (6): 339–343. PMID 9844789.
  • ^ George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, Nahas Z, Knable M, Fernandes P, Juncos J, Huang X, Nichols DE, Mailman RB (2007). "A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia". Schizophr. Res. 93 (1–3): 42–50. doi:10.1016/j.schres.2007.03.011. PMID 17467956. S2CID 31375175.
  • ^ Mu Q, Johnson K, Morgan PS, Grenesko EL, Molnar CE, Anderson B, Nahas Z, Kozel FA, Kose S, Knable M, Fernandes P, Nichols DE, Mailman RB, George MS (2007). "A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia". Schizophr. Res. 94 (1–3): 332–341. doi:10.1016/j.schres.2007.03.033. PMID 17596915. S2CID 25497605.
  • ^ Mailman R, Huang X, Nichols DE (2001). "Parkinson's disease and D1 dopamine receptors". Current Opinion in Investigational Drugs. 2 (11): 1582–1591. PMID 11763161.
  • ^ Salmi P, Isacson R, Kull B (2004). "Dihydrexidine--the first full dopamine D1 receptor agonist". CNS Drug Rev. 10 (3): 230–242. doi:10.1111/j.1527-3458.2004.tb00024.x. PMC 6741759. PMID 15492773.
  • ^ Zhang J, Xiong B, Zhen X, Zhang A (2009). "Dopamine D1 receptor ligands: where are we now and where are we going". Med Res Rev. 29 (2): 272–294. doi:10.1002/med.20130. PMID 18642350. S2CID 25334596.

  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Dihydrexidine&oldid=1167162033"

    Categories: 
    Drugs not assigned an ATC code
    D1-receptor agonists
    D2-receptor agonists
    D5 receptor agonists
    Catechols
    Biased ligands
    Antihypertensive agent stubs
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Articles with changed ChemSpider identifier
    Articles with changed EBI identifier
    Articles with changed InChI identifier
    Chemical pages without DrugBank identifier
    Articles without KEGG source
    Drugs with no legal status
    Drugboxes which contain changes to verified fields
    Drugboxes which contain changes to watched fields
    All stub articles
     



    This page was last edited on 26 July 2023, at 02:22 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki